Download: Lead Program in GBA-Parkinson’s Disease 

You joined Gain Therapeutics in 2020 when it was a private company and played a role in helping to take the company public.  What was

Listen to Podcast Watch the full presentation video of Computational Drug Discovery With Gain Therapeutics Matthias Alder In conversation with Mathias Alder, CEO of Gain

What scientific innovation are you most excited about? Which innovation do you think will have the most impact in the next 20 years? I don’t

Your educational background is in law. What was the trajectory of your career? Well, it was an evolution. Throughout my career, I’ve always been involved

Watch the full presentation video of Jeff Harman with Eric Richman, CEO of Gain Therapeutics: 00:01 I am Jeff Harmon 00:14 Eric Richman 00:19 Gain

Piper Sandler recently published a comprehensive report entitled “Deciphering the Artificial Intelligence / Machine Learning Matrix Code in Biotech.”  Why is this report significant? Technology

The Emerging Life Sciences Summit hosted by Oppenheimer will be on July 20th, 2022 in Montauk, NY.  This yearly conference brings together the who’s who

“While we continue to see exciting advances across the biopharma innovation landscape, sadly, new approaches and therapies for neurodegenerative diseases continue to remain largely elusive

Dr. Manolo Bellotto, General Manager and President of Gain Therapeutics, shares his personal story.  You can follow him on : Twitter : @ManoloBellotto LinkedIn : https://www.linkedin.com/in/manolobellotto/

We sat down and got a chance to speak with the General Manager and President of Gain Therapeutics, Dr. Manolo Bellotto. You can follow him

Gain Therapeutics will be providing an update on our lead compound in development for GBA-associated Parkinson’s disease, GT-02287 at the Jefferies Global Healthcare Conference. Recent

1. What initially sparked your interest in neuroscience? Science has always interested me. Even as a young child I wanted to be a scientist or

What is PROTAC? PROTAC, which is an acronym for proteolysis targeting chimera, is a class of heterobifunctional molecules that can be used to target specific proteins for degradation

Over 200 years ago, Dr. James Parkinson, a neurologist, geologist, and activist, published “An Essay on the Shaking Palsy” in 1817 which described the disease.

How do allosteric drugs compare to more traditional orthosteric drugs? Orthosteric drugs are compounds that bind to the active site of an enzyme. In order

What are prion diseases? Prion diseases are a group of neurodegenerative disorders that affect humans and other mammals. The most recognizable prion diseases are bovine

The presentation by Professor Zoe Cournia, who is at the Biomedical Research Foundation Academy of Athens in Greece, was about the power of supercomputing and

Professor Tiago Outeiro who is Professor of Aggregopathies and Director of the Department of Experimental Neurodegeneration at the University Medical Center in Gottingen, Germany, and

Presenting at Gain Therapeutics R&D Day, Manolo Bellotto, Ph. D elaborated on the Broad Application of Gain Therapeutics’ Structurally Targeted Allosteric Regulators (STARs). See the

Speaking at the Gain Therapeutics R&D Day, Dr. Xavier Barril, shared about discovering Novel Allosteric Targets by Combining Advances in Big Data and Computational Technology.

Manolo Bellotto, Ph. D gave an overview of Gain Therapeutics GBA program during Gain Therapeutics R&D Day. He explained how GBA program targets beta-glucocerebrosidase, or

During Gain Therapeutics R&D Day, Samuel Broder, MD shares his perspective on Neuroscience and Beyond. The title of his presentation was “The Role of Allosteric

Q: Dr. Xavier Barril, what was the evolution of your career?  A: I received my PhD in Biochemistry from the University of Barcelona in 2001

We have initially applied See-TX to selective protein misfolding diseases and have targeted lysosomal enzyme, to address the unmet medical needs of rare and neurodegenerative

What is allostery? Allo comes from the Greek allos which meaning “other.” Allosteric binding describes a ligand that binds a protein at a target site